Clinical Trial Update: Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of Interleukin-12 plus Rituximab in patients with Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Interleukin-12 (interleukin-12)
• Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Lymphoma | Phase 1 | Status: COMPLETED